EUVIMEDEUVIMED entdecken
Multizentrische Studie

Prevalencia de la enfermedad de Fabry en los pacientes con hipertrofia ventricular izquierda e insuficiencia renal (PrEFaCe)

Cristina García Sebastián, Vicente Climent Payá, Juan Carlos Castillo, José Ángel Urbano-Moral, Aurora Ruz Zafra, María José Valle Caballero, José Luis Zamorano, en representación de los investigadores del estudio PrEFaCe

Medicina Clínica · 2024

DOI: 10.1016/j.medcli.2024.06.009 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Medicina Clínica, 2024. Verfasst von Cristina García Sebastián und 7 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, España; Centro de Investigación Biomédica en Red de Enfermedades Cardiovascula…. Hauptthemen laut MEDLINE: Fabry Disease, Hypertrophy, Left Ventricular, Renal Insufficiency, Chronic. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Takeda Pharmaceuticals International AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION AND AIMS: Fabry disease (FD) causes glycosphingolipid accumulation in the vascular endothelium, with predominantly cardiac and renal involvement. Its prevalence in patients with concomitant involvement of these two organs is unknown. The objective of the study was to determine the prevalence of FD in patients with left ventricular hypertrophy and any degree of chronic kidney disease. PATIENTS AND METHODS: Patients with ventricular thickness ≥13mm and kidney disease from 29 Spanish hospitals were included. Sociodemographic variables and target organ involvement of FD were collected. Laboratory determinations of EF were carried out, with an enzymatic activity test±genetic test in men and direct genetic test in women. RESULTS: Eight hundred ninety-eight patients with left ventricular hypertrophy and chronic kidney disease were included. The presence of heart failure and cardiorenal syndrome was common (46.1% and 40.1%). Three patients (2 men and 1 woman) were diagnosed with FD, based on the presence of a pathogenic variant in the GLA gene and classic signs of FD, resulting in a prevalence of 0.33% (CI 95% 0.06-1%). Six patients (0.66%) presented genetic variants of unknown significance, without showing classic signs of FD, while in 13 patients (3.2%) performing the blood test was impossible. CONCLUSIONS: FD is an important cause of left ventricular hypertrophy and chronic kidney disease. Genetic diagnosis is crucial for avoiding biases and ensuring accurate identification of FD, especially in women. The results support the inclusion of this disease in the differential diagnosis of patients with ventricular hypertrophy ≥13mm and chronic kidney disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fabry DiseaseHypertrophy, Left VentricularRenal Insufficiency, ChronicHumansMaleFemalePrevalenceMiddle AgedAgedSpainAdultCardio-Renal Syndrome

Stichwörter der Autor:innen

Cardio-renal syndromeEnfermedad de FabryFabry diseaseHipertrofia ventricular izquierdaHypertrophy left ventricularInsuficiencia renal crónicaRenal insufficiency chronicSíndrome cardiorrenal

Autor:innen und Institutionen

  • Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, España; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, España. Electronic address: cristina.garcias01@…
  • Servicio de Cardiología, Hospital General Universitario Dr. Balmis, Alicante, España; Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, España.
  • Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, España; Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, España; Instituto Maimónides de Investigación Bi…
  • Unidad de Cardiopatías Hereditarias y Enfermedades del Miocardio; Hospital Universitario de Jaén, Jaén, España.
  • Hospital de la Serranía, Ronda, Málaga, España.
  • Hospital Universitario Virgen de la Macarena, Sevilla, España.

Förderung

  • Takeda Pharmaceuticals International AG

Zitieren

APA

García Sebastián, C., Climent Payá, V., Castillo, J. C., Urbano-Moral, J. Á., Ruz Zafra, A., Valle Caballero, M. J., Zamorano, J. L., & en representación de los investigadores del estudio PrEFaCe (2024). Prevalencia de la enfermedad de Fabry en los pacientes con hipertrofia ventricular izquierda e insuficiencia renal (PrEFaCe). Medicina Clínica. https://doi.org/10.1016/j.medcli.2024.06.009

Vancouver

García Sebastián C, Climent Payá V, Castillo JC, Urbano-Moral JÁ, Ruz Zafra A, Valle Caballero MJ, et al. Prevalencia de la enfermedad de Fabry en los pacientes con hipertrofia ventricular izquierda e insuficiencia renal (PrEFaCe). Medicina Clínica. 2024. doi:10.1016/j.medcli.2024.06.009

BibTeX
@article{GarcaSebastin2024,
  author = {García Sebastián, Cristina and Climent Payá, Vicente and Castillo, Juan Carlos and Urbano-Moral, José Ángel and Ruz Zafra, Aurora and Valle Caballero, María José and Zamorano, José Luis and en representación de los investigadores del estudio PrEFaCe, en representación de los investigadores del estudio PrEFaCe},
  title = {Prevalencia de la enfermedad de Fabry en los pacientes con hipertrofia ventricular izquierda e insuficiencia renal (PrEFaCe)},
  journal = {Medicina Clínica},
  year = {2024},
  doi = {10.1016/j.medcli.2024.06.009}
}
Kostenlos starten →